10 Questions to Ask Before Semax or Selank

Most prescriptions come with a U.S. package insert listing proven uses, side effects, and interactions. Semax and Selank do not. Both peptides are not FDA-approved, and a compounded Semax/Selank formulation is different from an FDA-approved drug and is not FDA-approved.

Without a U.S. label, the key questions to ask before Semax or Selank come from primary sources. A reviewing provider weighs small Russian studies, foreign product sheets, and FDA reviews against your medical history.

Why questions to ask before Semax and Selank start with symptoms and studies

1. Which symptoms are being evaluated, and how do they affect daily life? Anxiety, poor focus, low mood, and sleep trouble often overlap. A 2025 National Institute of Mental Health anxiety guide notes that evaluation starts with symptom timing, duration, frequency, and daily impact.

In its 2024 adult ADHD overview, the institute adds that clinicians check mood and medical conditions to rule out other causes first. Our guides to Semax for ADHD and Selank for anxiety explain how standard assessments differ from peptide studies.

2. What human evidence exists for each peptide and for the pair? Targeted PubMed searches identified no human trial of the combined Semax/Selank formulation. Human evidence comes mainly from small Russian studies on each separate peptide.

The English abstract of a 2008 Russian trial by Zozulia and colleagues compared 30 Selank patients with 32 on the sedative medazepam. All 62 had generalized anxiety disorder or neurasthenia (chronic nervous exhaustion). Authors reported similar anxiety scores on rating scales, without a placebo group, score gaps, or side-effect counts.

A 2020 Russian brain-imaging study tested 52 healthy adults across three separate groups: Semax (14), Selank (16), and placebo (22). Although the English abstract says injection, the Russian original confirms a single nasal dose before brain scans at 5 and 20 minutes. Those scans measured short-term brain connectivity, not symptom relief.

Medication lists, modified peptides, and medical history

3. Which medicines, supplements, and other nootropics are already in use? Human drug-interaction evidence for these peptides is very limited. The English abstract of a 2015 Russian study compared 30 anxiety patients on phenazepam alone with 40 taking phenazepam plus Selank.

That abstract reported earlier symptom relief and milder phenazepam side effects with the combination, without numerical rates. One phenazepam study does not establish compatibility with antidepressants, stimulants, sleep aids, or seizure drugs. The 2011 Russian 0.1% Semax instructions also call concurrent intranasal decongestants that narrow blood vessels undesirable.

A clinician also asks about other nootropics (compounds used for focus or memory), including N-acetyl Semax amidate. PubChem property records list different molecular formulas for N-acetyl Semax amidate and unmodified Semax. Because it is a distinct molecule, parent-peptide studies do not establish its effects.

4. Does a psychiatric or seizure history change the review? Both the Russian 0.1% sheet and the 2011 Russian 1% Semax instructions list contraindications. That section covers acute psychiatric conditions, disorders accompanied by anxiety, and a history of convulsions (seizures).

Those foreign sheets apply to specific Russian nasal products rather than a U.S. label, and they do not prove the pair causes seizures. Still, they explain why a provider reviews psychiatric and seizure history carefully.

5. Is there a bleeding history or blood-thinning medication? A July 24, 2026 FDA presentation noted possible anti-clotting properties for Semax. The FDA raised concern about bleeding risk, especially with existing bleeding risks or blood thinners.

The presentation also noted that Semax has no published human pharmacokinetic studies (research tracking how the body absorbs and clears a drug). A clinician may also consider blood pressure and cardiovascular history as part of a general health assessment. Our Semax side effects guide covers the evidence gaps.

Pregnancy, immune reactions, and FDA compounding status

6. How do pregnancy, plans to conceive, or breastfeeding affect the review? Russian Semax instructions contraindicate pregnancy and lactation (breastfeeding). Those sheets state that clinical studies were not conducted. Targeted PubMed searches identified no human pregnancy or breastfeeding safety trials for either peptide, so providers screen for both first.

7. Have past medicines or peptides caused an allergic reaction? Russian Semax sheets list hypersensitivity as a contraindication. They also note possible mild nasal irritation with prolonged use.

On the FDA safety-risks list, Selank acetate "may pose risk for immunogenicity for certain routes of administration." Immunogenicity means the capacity to trigger an immune response. FDA identifies clumping (aggregation) and peptide-related impurities as potential contributors to Selank acetate's risk.

That risk is not a measured allergy rate, and it differs from anaphylaxis, which MedlinePlus defines as a life-threatening allergic reaction. Still, a clinician reviews past drug reactions and emergency symptoms like throat swelling or breathing trouble, as covered in Selank side effects.

8. What is the current regulatory status, and who is accountable for the prescription? Semax and Selank are not FDA-approved. As the FDA compounding questions and answers page states, compounded drugs are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before marketing.

In a May 11, 2026 briefing memorandum, FDA staff proposed not adding Semax free base or acetate to the 503A bulks list. The Pharmacy Compounding Advisory Committee met July 23–24, 2026 to review Semax; advisory committees make non-binding recommendations to the FDA. As of October 17, 2026, the day this article was written, the FDA has not issued a final rule on Semax.

Both Semax and Selank acetate (TP-7) appear on the FDA safety-risks page under bulk nominations that were withdrawn. An October 14, 2026 federal regulatory entry also shows a pending review for an interim peptide compounding policy, without naming specific molecules. A licensed provider may still prescribe — that decision is between you and your doctor.

Semax/Selank prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy. Standalone Semax and Selank are coming soon to Promise as compounded medications, which are different from an FDA-approved product: the formulations Promise will offer will not be FDA-approved.

Drug-tested sports and how follow-up works

9. Does competing in drug-tested sports require a separate anti-doping review? On September 21, 2026, the World Anti-Doping Agency announced its 2027 Prohibited List. As of October 17, 2026, the day this article was written, the 2027 Prohibited List is published and takes effect on January 1, 2027.

Neither Semax nor Selank is named on the 2027 list, but the 2027 WADA explanatory note warns that unnamed peptides may still be prohibited. Section S0 bans unaddressed substances lacking current approval by any governmental health authority worldwide. Because Russian registration exists for Semax and prescriptions do not automatically grant a therapeutic use exemption, athletes check with their anti-doping organization.

10. How is progress tracked, and when does the plan change? Published studies used rating scales or brief brain scans. They do not supply a validated monitoring or stopping schedule for the pair. The reviewing clinician sets baseline goals, follow-up timing, and the symptoms that require stopping or urgent care.

At Promise, a licensed provider reviews every request, and not everyone qualifies.